Stockhead on MSN9h
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.
domain-b.com19h
AstraZeneca acquires EsoBiotec in $1 bn deal
British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...